Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda.
Clin Infect Dis. 2021 Aug 2;73(3):513-520. doi: 10.1093/cid/ciaa703.
Limited evidence suggests that the nonhormonal contraceptive copper intrauterine device (Cu-IUD) may increase bacterial vaginosis (BV) risk, possibly due to increased volume and duration of menses, a common side effect of Cu-IUD use. Although increases in bleeding typically resolve within 6-12 months following initiation, evaluations of the association between Cu-IUD and BV have not included more than 6 months of follow-up.
This secondary analysis of a human immunodeficiency virus type 1 prevention trial included 2585 African women ages 18-45 followed for up to 33 months. Women reported contraceptive use each month. BV was evaluated by Nugent score in 6-monthly intervals and, if clinically indicated, by Amsel criteria. Andersen-Gill proportional hazards models were used to (1) evaluate BV risk among Cu-IUD users relative to women using no/another nonhormonal contraceptive and (2) test changes in BV frequency before, while using, and following Cu-IUD discontinuation.
BV frequency was highest among Cu-IUD users at 153.6 episodes per 100 person-years (95% confidence interval [CI]: 145.2, 162.4). In adjusted models, Cu-IUD users experienced 1.28-fold (95% CI: 1.12, 1.46) higher BV risk relative to women using no/another nonhormonal contraception. Compared to the 6 months prior to initiation, BV risk was 1.52-fold (95% CI: 1.16, 2.00) higher in the first 6 months of Cu-IUD use and remained elevated over 18 months of use (P < .05). Among women who discontinued Cu-IUD, BV frequency was similar to pre-initiation rates within 1 year.
Cu-IUD users experienced elevated BV risk that persisted throughout use. Women and their providers may wish to consider BV risk when discussing contraceptive options.
有限的证据表明,非激素避孕的铜宫内节育器(Cu-IUD)可能会增加细菌性阴道病(BV)的风险,这可能是由于 Cu-IUD 使用导致月经血量和经期延长,这是 Cu-IUD 使用的常见副作用。虽然在开始使用后的 6-12 个月内,出血通常会得到解决,但对 Cu-IUD 与 BV 之间关联的评估并未包括超过 6 个月的随访。
这项人类免疫缺陷病毒 1 型预防试验的二次分析包括 2585 名年龄在 18-45 岁的非洲女性,随访时间长达 33 个月。女性每月报告避孕措施的使用情况。每 6 个月通过 Nugent 评分评估 BV,如有临床指征,通过 Amsel 标准评估。Andersen-Gill 比例风险模型用于(1)评估 Cu-IUD 使用者相对于不使用/使用其他非激素避孕方法的女性的 BV 风险,以及(2)测试 Cu-IUD 停用前、使用期间和停用后 BV 频率的变化。
Cu-IUD 使用者的 BV 频率最高,每 100 人年 153.6 例(95%置信区间 [CI]:145.2,162.4)。在调整后的模型中,Cu-IUD 使用者的 BV 风险是不使用/使用其他非激素避孕方法的女性的 1.28 倍(95%CI:1.12,1.46)。与开始前的 6 个月相比,Cu-IUD 使用的前 6 个月 BV 风险增加 1.52 倍(95%CI:1.16,2.00),在使用 18 个月后仍处于较高水平(P<0.05)。在停用 Cu-IUD 的女性中,一年内 BV 频率与开始前的比率相似。
Cu-IUD 使用者的 BV 风险增加,并持续存在于整个使用期间。当讨论避孕选择时,女性及其提供者可能需要考虑 BV 风险。